Avalon's Sweat Equity
This article was originally published in Start Up
Executive Summary
Avalon Ventures closed its ninth fund in January with $200 million committed, $50 million more than planned and a third larger than its previous fund. For a firm that invests half its money in tiny lifescience start-ups, it was an impressive number at a time when the venture industry is reeling. That’s a vote of confidence in the firm’s unusual "sweat equity" strategy.
You may also be interested in...
Venture Firm Avalon Turns To GSK To Share Biotech Risk
Entering its fourth decade, Avalon fights through “dark days” and taps GlaxoSmithKline to help fund its next crop of early-stage start-ups. In exchange, it must deliver assets, not platforms, to trigger a GSK acquisition of those start-ups, with pre-arranged returns.
BIO 2013 Monday Roundup: Bayer, Orphan Drug Pricing, Avalon/GSK
Our survey of news from the first day of BIO 2013 includes a look at Bayer’s business development plans, Avalon Ventures’ tie-up with GlaxoSmithKline, and news from panel discussions on orphan drugs, venture philanthropy and Russia.
RQx Antibiotic Collaboration With Genentech Marks Third Exit For Avalon Ventures This Year
Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.
Need a specific report? 1000+ reports available
Buy Reports